Authors: V. Vachalovský; J. Dvořáček Authors‘ workplace: Urologická klinika 1. LF UK a VFN, Praha Published in: Čas. Lék. čes. 2002; : 669-672 Category:
Intermittent endocrine treatment or cyclic therapy of prostate cancer aims at prolonging survival by delayingprogression to androgene independence and at improving quality of life by avoiding the side effects of continuousandrogen ablation. Intermittent endocrine treatment is capable of inducing multiple apoptoic regressions and ofimprovement in quality of life including sexual functions. The recommended lenght of therapeutic period is 6–9months. The mean off-therapy interval approaches 50 % of the duration of the treatment cycle. The mean time todisease progression is 32 month. The definitive answer to the question of prolonged survival awaits the completionof ongoing randomized studies.
Key words: prostate cancer, intermittent androgen treatment.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
